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Antiviral restrictionsCurrent treatment of HIV/AIDS consists of a combination of three to ﬁve agents targeting different viral
proteins, i.e. the reverse transcriptase, protease, integrase and envelope, and aims to suppress viral
replication below detectable levels. This “highly active antiretroviral therapy” (HAART) has brought an
enormous beneﬁt for life expectancy and quality in HIV-1-infected individuals, at least in industrialized
countries. However, signiﬁcant limitations with regard to efﬁciency, drug resistance, side effect and costs still
exist. Recent data suggest that cellular factors also represent useful targets for therapy. Here, we summarize
ﬁndings from several genome-wide screens that identiﬁed a large number of cellular factors exploited by
HIV-1 at each step of its life cycle. Furthermore, we discuss the evidence that humans are equipped with
powerful intrinsic defense mechanisms against retroviruses but that HIV-1 has evolved elaborate ways to
counteract or evade them. Preventing the use of host cell proteins obligatory for viral replication or
strengthening the cellular defense mechanisms may help to reduce viral replication to harmless levels. A
better understanding of the host factors that promote or restrict HIV-1 replication may thus lead to the
development of novel therapeutics against HIV/AIDS.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Currently, more than 25 antiretroviral drugs are available to treat
human immunodeﬁciency virus (HIV) infection. The great majority of
them target the HIV-1 reverse transcriptase (RT) (nucleoside and
nucleotide RT inhibitors: zidovudine, didanosine, zalcitabine, stavu-
dine, lamivudine, abacavir, emtricitabine and tenofovir and non-
nucleoside RT inhibitors: nevirapine, delavirdine, efavirenz and
etravirine) and the viral protease (saquinavir, ritonavir, indinavir,
nelﬁnavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir
and darunavir) (Fig. 1). More recently, antiretroviral drugs that inhibit
the viral integrase (IN) (raltegravir) or the six-helix bundle core
formation of the gp41 transmembrane protein required for virus–cell
fusion (enfuvirtide) have been approved for the clinic [1]. While this
growing repertoire of antiretroviral agents is impressive, none of these
drugs is useful for the treatment of HIV/acquired immunodeﬁciency
syndrome (AIDS) on its own because HIV-1 is highly variable and
capable of developing resistance against all of them. This high genetic
variability provided the rationale for the development of “highly active
antiretroviral therapy” (HAART) consisting of combinations of three or
more antiretroviral agents. HAART aims to suppress viral replication to
such low levels that the emergence of drug-resistant HIV-1 variants is
prevented. Furthermore, while the diverse HIV-1 species (called quasi-
species) found in a single individualwillmost likely already contain theat tel.: +33 1 40613599; fax:
fax: +49 731 50065131.
l),
ll rights reserved.genetic changes reducing its susceptibility to single drugs, it is more
difﬁcult for the virus (and sometimes associated with decreased
“ﬁtness”) to acquire the complex combination of mutations required
for multi-drug resistance.
Treatment of HIV-1-infected individuals by HAART usually
allows to reduce the plasma viral load to undetectable levels,
improves CD4+ T cell counts, delays disease progression and
promotes survival. However, although the development of HAART
was certainly the greatest success of AIDS research and allows the
reduction of morbidity and mortality wherever it is available, it also
has major limitations. Furthermore, HAART is expensive and requires
an infrastructure with a functional health care system allowing the
medical monitoring of the success of antiretroviral therapy to prevent
or at least delay the emergence of drug-resistant HIV-1 strains. The
vast majority of ∼34 million people currently infected with HIV-1 live
in developing countries and– althoughaccess to antiretroviral drugs in
the developing world is improving – most of them still do not have
access to antiretroviral therapy [2,3]. Thus,whileHAART constitutes an
effective approach for the treatment of AIDS and also prevents HIV-1
transmission by reducing the viral loads, it still has little impact on the
global spread of the virus (∼2.5 million new HIV infections per year)
and the global number of fatalities caused by AIDS (∼2 million per
year). Life expectancy has drastically fallen in some countries that are
most severely affected by HIV/AIDS, e.g. in Zimbabwe it is only
34 years for women and 37 years for men [2]. Even under optimal
conditions, HAART has signiﬁcant drawbacks, e.g. it is frequently
associated with signiﬁcant side effects (such as metabolic and
cardiovascular disorders), with immune reconstitution disease, and
with the development of resistant HIV-1 strains (particularly in the
Fig. 1. Viral replication cycle and the steps currently inhibited by HAART. Viral proteins involved in the individual steps are indicated in black and antiretroviral agents blocking them
in blue.
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requires life-long daily treatment because it does not allow to
eliminate resting long-lived cells containing integrated proviruses
and thus fails to eradicate the virus entirely.
Because of the drawbacks of current combination antiretroviral
therapy, it remains amajor interest to develop new antiretroviral drugs
or innovative therapies to reduce undesired side effects, to prevent the
emergence of drug resistance or even to attack the viral reservoirs [4,5].
Indeed, amajorbarrier to curingHIV infection remains the ability ofHIV
to integrate in the host genome and remain latent. The thus-generated
viral reservoirs cause viral rebound upon HAART interruption and
impose lifelong antiretroviral therapy with its many associated side
effects and possible development of resistance. Here, we focus on
approaches aiming to target cellular rather than viral proteins. It is long
known that HIV-1 utilizes host factors at many steps of its life cycle.
However, currently only a single drug targeting a cellular protein has
been approved for the clinic: Maraviroc binds to the HIV-1 entry
cofactor CCR5 and blocks its interaction with the viral envelope gp120
to prevent the membrane fusion events necessary for viral entry [6].
Recent studies using genome-wide screening technologies have
identiﬁed large numbers of host factors that may be required for
virus replication and thus represent potential therapeutic targets [7–9].
Another recent development is the realization that humans are
equipped with factors that directly inhibit retroviruses [10,11]. For
example, tripartite motif 5-alpha (TRIM5α) proteins can block
incoming retroviral capsids in a species-speciﬁc manner [12] and the
cellular apolipoprotein BmRNA-editing enzyme, catalytic polypeptide-like 3 (APOBEC3) cytidine deaminase induces lethal hypermutation of
the viral genome [13]. Finally, the recently discovered restriction factor
“tetherin” (also called BST-2, HM1.24 or CD317) inhibits HIV-1 particle
release [14,15]. These ancient antiviral defense mechanisms were
obviously quite successful in past encounters with retroviruses since
about 8% of the human genome is of retroviral origin [16]. HIV-1,
however, has evolved the ability to counteract these by several
“accessory” viral proteins (Viral infectivity factor (Vif), viral protein U
(Vpu)) or can avoid them by its high variability and is thus capable to
replicate efﬁciently in the hostile environment of the human cell
[10,11]. Strengthening these cellular defense mechanisms or weaken-
ing the viral antagonists may help to control HIV-1 replication.
2. Host factors as targets for antiretroviral therapy
2.1. Targeting viral entry
All viruses are obligate intracellular parasites without an inde-
pendent metabolism and thus strictly dependent on their target cells
for reproduction. The ﬁrst cellular factor shown to be required for
HIV-1 replication is the primary viral CD4 receptor that has been
discovered more than two decades ago and determines the viral
tropism for CD4+ T cells and tissue macrophages [17]. A variety of
strategies has been pursued to block the interaction between the
external viral envelope glycoprotein gp120 and CD4. These include
soluble CD4 or CD4 mimics that seem to induce a non-functional
conformation of gp120, small molecule inhibitors that target the
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CD4 antibody (TNX-355) has shown some beneﬁcial effects in clinical
studies [19] and seems to act synergistically with enfuvirtide (T20)
that interacts with gp41 and blocks a later step in the viral entry
process [20]. However, TNX-355 has the disadvantage that it is not
orally bioavailable and currently no CD4 inhibitor has been approved
for the clinic.
Ten years after the discovery of CD4 as primary receptor of HIV,
the seven-transmembrane G protein-coupled chemokine receptors
CCR5 and CXCR4 were discovered as critical coreceptors for HIV-1
entry [21–25]. Shortly thereafter, several groups reported that a
homozygous deletion in the CCR5 allele (Δ32/Δ32), naturally
occurring in about 1% of the Caucasian population, protects against
HIV-1 infection and is not associated with signiﬁcant immunological
dysfunction [26–28]. Moreover, it was observed that heterozygous
deletions in CCR5 are associated with delayed disease progression
[27–29]. Altogether, these results suggested that CCR5 is a promising
cellular target for anti-HIV therapy because its blockade should be
well-tolerated and effective in inhibiting CCR5-tropic (R5) HIV-1
strains. Initially, several modiﬁed forms of the natural CCL5/RANTES
(regulated upon activation, normal T cell expressed and secreted)
ligand of CCR5 have been developed [30]. These agents compete with
the HIV-1 gp120 for CCR5 binding and some of them (e.g. PSC-
RANTES) are highly effective in vitro and in the human peripheral
blood lymphocyte-severe combined immunodeﬁcient (SCID) mouse
model [30,31]. Although they failed in clinical trials, PSC-RANTES is
currently further evaluated as potential microbicide against HIV
[32,33]. Another strategy was the development of small molecule
inhibitors that bind to a hydrophobic pocket in CCR5 and seem to
inhibit HIV infection by inducing conformational changes rather than
by direct occupation of the gp120 binding site [18]. One of these
inhibitors, maraviroc, has been approved by the US Food and Drug
Administration (FDA) and the European Medicine Agency for the
treatment of viremic patients harboring multi-resistant HIV-1 strains.
Thus, maraviroc is currently the only antiretroviral drug targeting a
cellular factor used in the clinic [34]. However, several related agents,
such as vicriviroc, and anti-CCR5 antibodies are currently evaluated
in clinical trials [35,36].
An alternative approach is the speciﬁc knock-down of CCR5 using
RNA interference. Although this method usually only achieves partial
knock-down of the target sequence, one study achieved the complete
knock-out of CCR5 in hematopoietic stem cells using a stable RNA
interference system, which then conferred resistance to HIV-1
infection to the in vitro derived macrophages [37]. More recently,
the speciﬁc delivery of CCR5 siRNAs to T cells in a humanized mouse
model was reported to suppress viremia and prevent CD4 T cell
depletion [38]. Work is underway to reduce induced cytotoxicities to
adapt siRNA-mediated knock-down of CCR5 for clinical application.
These strategies have recently obtained substantial impetus by the
spectacular report of a Δ32/Δ32 allogenic stem cell transplantation in
an HIV-1-positive leukemia patient, which led to long-term control of
viral replication (for more than 2 years) in the absence of
antiretroviral therapy [39]. Since HIV-1 usually only requires a few
amino acid changes to switch from CCR5 to CXCR4 coreceptor usage
[40], this is a highly unexpected and encouraging ﬁnding. The
transplantation of CCR5-negative allogenic stem cells for the
treatment of malignancies in HIV-1-positive patients holds some
promise, particularly if the worldwide bone marrow and cord blood
donor banks agree to merge CCR5-screening information into one
database system [41]. A more general approach would be to knock-
down CCR5 in wild-type CD34+ stem cells using RNA interference
before transplantation. In order to be successful, this approach would
have to allow the speciﬁc expansion of the transgenic cells in vivo
since it is unlikely that gene transfer (of an siRNA expressing cassette)
is achieved in all cells of the transplant. However, HIV-1 may facilitate
this selection by causing a speciﬁc depletion of CCR5-expressing cells.Although the inhibition or knock-down of CCR5 using small
inhibitor molecules or gene therapy transfer protocols is promising, it
also has some drawbacks. One concern is that CCR5 may play a role in
immunity against some pathogens [42]. Another disadvantage is that
it is not active against X4 HIV-1 strains. Obviously, the best approach
would be to combine CCR5 and CXCR4 inhibitors [43]. However, in
contrast to CCR5, CXCR4 is essential for various physiological
processes and its knock-out is lethal in mice [44,45]. Several potent
inhibitors of CXCR4, such as AMD3100 or AMD070, have been
developed but clinical development was halted due to undesired
side effects or lack of antiviral effects [1,18]. Notably, however,
AMD3100 has been approved by the FDA as a stem cell mobilizer for
transplantation under different names (Plerixafor or Mozobil).
Several new anti-CXCR4 agents are in development and the CXCR4/
SDF-1 pathway is emerging as an appealing target for the treatment of
certain forms of cancer [46]. Thus, potent and better-tolerated CXCR4
inhibitors may become available in the future and complement
antiretroviral therapies targeting CCR5.
2.2. Other cellular targets for antiretroviral therapy currently investigated
HIV-1 entry is a particularly promising step for intervention
because it involves several relatively well-deﬁned interactions in the
cell membrane that can be blocked without the inhibitor entering the
cells [47]. Furthermore, blocking HIV-1 at this early step prevents the
integration of the proviral genome into that of the host cell and hence
the establishment of latent viral reservoirs. However, the HIV-1
replication can in theory be inhibited at each step of its cycle in order
to block viral spread. Thus, the inhibition of HIV-1 uncoating, reverse
transcription, integration, transcription, assembly and release from
the cell membrane (Fig. 1) all represent valid approaches to tackle
HIV-1 infection and are currently being investigated.
An early therapeutic approach sought to target the HIV cofactors
Tat and Rev, which are essential for viral replication and, to a large
extent, functionally dependent on well-deﬁned cellular factors [48].
Tat promotes the elongation of viral transcripts by binding to the
transactivation response element (TAR) located in the HIV long-
terminal repeat (LTR) and acts as an adaptor for the recruitment of the
positive transcription elongation factor b (P-TEFb) [49], which is a
heterodimer of cyclin T1 and cyclin-dependent kinase 9 (Cdk9). Since
recruitment of P-TEFb to the TAR is both necessary and sufﬁcient for
HIV-1 transcription [50], targeting P-TEFb may constitute a good
approach for anti-HIV therapy. A number of small compounds that
inhibit Cdk9 or cyclin T1 activities, or that disrupt the Tat/TAR/P-TEFb
interaction have been tested [51,52]. However, since P-TEFb is
necessary for the transcription of many cellular genes [53], ﬁnding
an inhibitor that exclusively blocks HIV transcription has proven
difﬁcult. Rev mediates the nuclear export of unspliced viral RNA
through interaction with the cis-acting Rev response element (RRE)
located in the HIV env gene [54,55]. The shuttling of Rev between the
nucleus and the cytoplasm is dependent on a number of cellular
proteins, including the RNA helicase DDX3X, CRM1, Ran-GTP as well
as nucleoporins, importins and Sam 68 [54–56]. Targeting of DDX3X
or other DEAD-box helicases by RNA interference has been reported to
suppress Rev function and inhibit HIV replication [57–59]. Interest-
ingly, the Tat cofactor CCNT1/cyclin T1 and the Rev cofactor DDX3X
were identiﬁed in two of the three siRNA screens of host factors
implicated in HIV-1 infection [7–9]. However, although Tat and Rev
represent useful targets for antiretroviral drug development, no
speciﬁc agents inhibiting them or their cellular cofactors without
signiﬁcant side effects have yet been developed.
The recent addition of an HIV-1 IN inhibitor (raltegravir) to the
available HAART drugs indicates that targeting proviral integration is a
useful approach. HIV-1 IN interactswith a cellular factor thatmay have
potential as a therapeutic target: the cellular lens epithelium-derived
growth factor (LEDGF)/p75 [60], a chromatin-associated protein that
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between HIV-1 IN and LEDGF/p75 leads to impaired viral replication
[62]. The crystal structure of the interaction interface has been
resolved [63,64] and the development of a small inhibitor to preclude
LEDGF/p75–IN binding is conceivable but remains challenging [65].
Although post-integration, the inhibition of particle budding from
the plasma membrane and/or cell-to-cell transfer of the virus is a
valid approach to prevent viral spread. HIV-1 usurps the cellular
Endosomal Sorting Complex Required for Transport I (ESCRT-I) for its
release from infected cells [66–68]. In particular, the PTAP-type late
domain of the HIV-1 Gag precursor polyprotein interacts with TSG101
(tumor susceptibility gene 101), a cellular protein normally involved
in endosomal protein sorting, and inhibition of this interaction or
depletion of TSG101 by RNA interference suppresses HIV-1 particle
release [69–71]. One therapeutic approach would consist in develop-
ing molecules, which would mimic the viral PTAP motif, such as cyclic
peptides [72]. Another potentially interesting interaction has also
been identiﬁed betweenHIV-1 Gag and the endosomal sorting protein
Alix [73,74].
2.3. Genome-wide screens reveal numerous potential targets for
antiretroviral therapy
Although many cellular factors were already known to be required
for HIV infection, the recent application of technological advances to
the study of HIV infection revealed that we were actually only seeing
the tip of the iceberg. Three independent genome-wide RNA
interference-based screens evaluated more than 20,000 human genes
for their relevance in infection [7–9]. Altogether, these studies
identiﬁed a total of 842 genes that reduce HIV-1 infection when
knocked-down. Another study used an alternative approach and
genotyped a large group of HIV-1-infected individuals to identify
human genetic differences that inﬂuence the vulnerability to HIV-1
infection and clinical outcomeof infection [75], thus adding a further 63
genes to the list. Recently, the National Library of Medicine made
available a comprehensive list of all cellular proteins shown to interact
physically or functionally with HIV-1 (Human Protein Interaction
Database) [76–78]. Taken together, these studies and databases
identiﬁed a total of 1,254 genes that may play a role in HIV-1Table 1
Selected host factors involved in HIV-1 infection.
Category Example
Surface molecules Clusters of differentiation; integrins; chemoki
Endocytosis Caveolin; clathrin; COPI system of vesicular tr
Intracellular receptors Steroid receptors; nuclear receptors
Signaling Ras family; tyrosine and serine/threonine kin
Cytoskeleton Actin, microtubule, and intermediate ﬁlament
Proteasomal degradation Proteasome subunits; ubiquitin-conjugating e
Lysosomal degradation Breakdown enzymes; vacuolar ATPases
Nuclear import Nucleoporins; karyopherins; Ran binding pro
Chromatin Histones; histone clusters; histone deacetylas
Transcription & DNA binding Transcription factors; co-activators; transcrip
Nuclear export RNA export factors; nuclear export signal dep
RNA splicing Splicing factors
Translation and RNA binding Translation initiation factors; translation elon
translocation
Protein assembly/protein–protein
interactions
Tripartite motif proteins; ankyrin repeat dom
Protein modiﬁcations Acetyltransferases; myristoyltransferases; pep
Metabolism Isomerases; glycosyltransferases; convertases
Apoptosis Inducers of apoptosis
Cell cycle & proliferation Cyclins, cyclin-dependent kinases; cell divisio
Multivesicular body formation ESCRT machinery; synaptic proteins
Cytokines and secreted proteins Interleukins; tumor necrosis factor
Others Antioxidants/metal binding; ion channels; co
Shown are examples of host factors identiﬁed more than once in databases of host protein
(SNPs) proposed to be associated with disease progression and of host proteins reported to i
relevance of most of these cellular factors in primary HIV-1-infected cells remains to be coreplication [79]. Many of these genes are involved in speciﬁc pathways
(proteasomal targeting, transcription, immune response, RNAbinding/
splicing, chaperones, etc.) that are usurped by HIV-1 (summarized in
Table 1).
The whole-genome siRNA screens, which expand the information
brought by a previous subgenomic screen [80], provide important
new insights on the host factors involved in HIV-1 early steps of
replication. However, some caution must be taken in interpreting this
newly available source of information. Firstly, the siRNA screens show
only poor overlap: only three of the 842 HIV-dependency factors were
obtained in all three studies: MED6, MED7 and RELA. The reason for
this poor overlap lies possibly in differences in the cell lines used
(HeLa and HEK293T), the multiplicity of siRNA coverage for each
gene, the steps of the HIV replication cycle investigated, the time
points analyzed and the ﬁltering thresholds used [79]. Secondly, the
use of cell lines (i.e. HeLa and HEK293T) that are not usually infected
by HIV-1 and of pseudotyped virions limits the relevance of some of
these results. Recently however, a genome-wide siRNA-based screen
was carried out in Jurkats, thus identifying a further 252 genes
involved in HIV-1 infection, only 6 of whichwere also identiﬁed by the
3 siRNA screens carried out in HeLa and HEK293T [81]. Thirdly, the
siRNA screens focus per deﬁnition on proteins whose functions may
be knocked-down without overt cytopathic effect, in other words, for
proteins that are either functionally redundant or that are not
essential for cellular function. Fourthly, it is likely that many hits
represent false-positives in terms of physiological relevance since the
studies only look at virus infection in cell lines as experimental end-
point and it is by no means certain that these play signiﬁcant roles in
HIV-1 infected individuals. These points, together with the partial
knock-down nature of RNA interference, probably account for the fact
that some cellular factors already known to be important for HIV-1
infection were missed by the genome-wide surveys (e.g. LEDGF/p75).
Despite some limitations, the genome-wide screens and surveys of
HIV infection provide a good starting point for the identiﬁcation of
cellular targets for HIV therapy. Cellular factors that were identiﬁed in
at least two of the three siRNA screens and are listed in the HIV
interaction database represent particularly interesting candidates.
Eleven proteins fulﬁll this criterion: the nucleoporin Nup153, CD4 and
CXCR4, the kinases Jak1 and Akt1, the NFkB subunit RelA, fournes; MHC; lectins; syndecans; inositol triphosphate receptor
ansport
ases; phosphatases; cAMP phosphodiesterases
components and associated proteins
nzymes, ligases and other associated proteins
teins
es; chromatin modifying proteins; regulators of DNA repair/telomere length
tion elongation factors; RNA polymerases; mediator complex; DNA binding proteins
endent transport
gation factors; RNA helicases; ribonuclear proteins; ribosome-associated; protein ER
ains; heat shock proteins; chaperones
tidases; proteases
; phospholipases and other metabolic enzymes
n control proteins
mplement
s whose knock-down attenuates HIV-1 infection, of single-nucleotide polymorphisms
nteract with one or more viral component [7–9,75–79]. The list is not complete and the
nﬁrmed.
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sulfotransferase of HIV-1 envelope [79]. Other interesting candidates
are those appearing in three or more gene sets from a total of 12 that
are currently available for factors identiﬁed as relevant for HIV
replication [79]. In this case, 49 genes fulﬁll this criterion including
Nup98, Nup153 and hnRNP1, all of which are thought to play a role in
HIV nuclear import as well as TSG101 involved in virion assembly
[79]. Proteasomal and lysosomal subunits, chaperones, heat shock
proteins and transcription/translation factors also constitute multiple
hits, but whether these are sufﬁciently important for HIV replication
as to constitute a good drug target and can be selectively inhibited
without cellular toxicity remains to be determined. These future
studies and further improved RNAi-based screens have the potential
to identify essentially all cellular cofactors required in the different
steps of the HIV-1 life cycle and will undoubtedly not only greatly
improve our understanding of host/HIV interactions but also lead to
the development of new antiretroviral agents.
3. Host factors restricting HIV-1 replication
It is well appreciated that HIV uses many cellular factors to
complete its life cycle. Only in recent years, however, has it become
clear that the host cell is not a friendly environment for HIV since
several host proteins have been identiﬁed as intrinsic immunity
factors that most likely evolved speciﬁcally as defense against viralFig. 2. Intrinsic host restriction factors and their viral antagonists. As schematically indica
uncoating by proteasomal degradation. The accessory viral Vif protein binds to a Cullin5-ba
latter in proteasomes. In the absence of Vif, APOBEC3G is incorporated into the budding virion
infection. Tetherin prevents the release of nascent mature viral particles from the cell surfac
remains to be identiﬁed but may involve direct interaction and beta-TrCP2-dependent deginfections [10,11]. These host restriction factors interfere with
retroviral replication by diverse mechanisms and can protect
mammals from cross-species transmission of retroviruses. Three
classes of retroviral restriction factors have so far been identiﬁed:
cytidine deaminases (e.g. APOBEC3G), which induce lethal hyper-
mutations of the retroviral genome [82,83], Fv1/TRIM5α proteins,
which restrict the incoming retroviral capsid [84,85], and tetherin,
which impedes the release of nascent HIV virions from the cell surface
[14]. Recent analyses have shown that these host restriction factors all
evolved under positive selective pressure due to past encounters with
ancient viruses [86–89]. Overall, they were obviously quite successful
since a large part of our genome (about 8%) consists of silenced
retroviral sequences [16] and are still active against endogenous and
exogenous invaders [90,91]. Notably, most restriction factors have
broad antiviral activity and strengthening them may have beneﬁcial
effects against different pathogens [10,11,91].
APOBEC3G was the ﬁrst host gene identiﬁed as an inhibitor of
HIV-1 infection [13]. APOBEC3G is a cytidine deaminase that
introduces G-to-A substitutions in the HIV-1 genome, which are
detrimental to viral replication (Fig. 2). It has been reported that high
levels of hypermutation in the provirus are associated with higher
CD4 T cell counts in infected individuals [92], although not with
reduced viral loads [93,94]. Accumulating evidence suggests that
some of the antiretroviral activity of APOBEC3 is independent of its
mutator activity and may involve direct effects on reverseted, TRIM5α interacts with the incoming HIV-1 capsids and may induce accelerated
sed ubiquitin ligase complex and to APOBEC3G (3G) to induce the degradation of the
s and causes lethal G-to-A hypermutations of the retroviral genome in the next round of
e and is antagonized by Vpu. The exact mechanism by which Vpu counteracts tetherin
radation of tetherin leading to its sequestration from budding virions.
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to the therapeutic inhibition of Vif, which antagonizes APOBEC3G by
proteasome-mediated degradation and blocking its incorporation
into nascent particles [95,96]. A different approach would be to boost
the intracellular levels of APOBEC proteins through interferon-alpha
treatment [97,98] or by targeting the Vif-APOBEC interaction domain.
Alternatively, small molecules may be designed to enhance the
catalytic activity of APOBEC3G in the cell. However, in order to
consider APOBEC family members as potential targets for anti-HIV
therapy, it will be important to clarify the relative contribution of the
enzymatic and non-enzymatic activities of APOBEC to the observed
restriction of viral replication and to elucidate whether these operate
mainly in virions prior to infection or in the cytoplasm of infected
cells.
TRIM5α proteins block retroviral infection of primate cells in a
species-speciﬁc manner and were originally discovered as important
determinants of the resistance of monkey cells to HIV-1 infection [12].
The mechanisms that lead to virus inactivation by TRIM5α proteins
are not well understood [11]. It is thought, however, that the incoming
viral capsids are rapidly uncoated upon entry into the cytoplasm of
the host cell [99] and that the C-terminus of TRIM5α interacts directly
with the viral capsid and determines its antiretroviral speciﬁcity
[99,100]. HIV-1 is speciﬁcally blocked by TRIM5α from Rhesus
macaques and Owl monkeys but only weakly restricted by human
TRIM5α [84,85]. Therefore, the therapeutic targeting of TRIM5α for
treatment of HIV-1 infection may be achieved by gene therapy
mediated delivery of rhesus or owl monkey TRIM5α variants. Since
these proteins are not human, a concern may be that modiﬁed cells
would be eliminated by an immune response in treated patients.
Furthermore, it remains to be elucidated whether HIV-1 can develop
resistance against the monkey TRIM5α variants. Recently, chimeric
forms of human–rhesus and human–owl TRIM5α were reported to
restrict HIV-1 in transduced primary cells and in humanized mouse
models [101,102], thus validating chimeric forms of TRIM5α as
potential candidates for anti-HIV-1 gene therapy. Alternatively, it may
be possible to develop compounds that promote the binding of
TRIM5α to HIV-1 capsids or interact directly with the capsids to
inactivate them. Finally, it is noteworthy that other members of the
TRIM family, such as TRIM22, may have activity against HIV-1
[103,104]. Thus, the induction of some TRIM proteins may help to
limit HIV-1 replication.
The most recently identiﬁed restriction factor, tetherin (also
known as BST-2, CD317, or HM1.24), inhibits viral spread by
“tethering” fully formed mature virions on infected cell surfaces and
preventing them from budding [14,15]. Tetherin has broad antiviral
activity: it inhibits a wide range of retroviruses as well as ﬁlo- and
arenaviruses. Pandemic HIV-1 strains use their Vpu protein to
antagonize tetherin [14,15,105]. In comparison, SIVs that lack a vpu
gene counteract this restriction factor by their multi-functional
accessory Negative factor (Nef) proteins [106,107] and HIV-2 and
Ebola viruses seem to antagonize tetherin by their envelope
glycoproteins [108–110]. The mechanisms by which these viral
factors antagonize tetherin are not well understood but Vpu seems
to sequester tetherin from the site of budding [14,110], reduce its
surface expression [15] and promote its beta-TrCP2-dependent
proteasomal degradation [111,112]. The expression of tetherin is
inducible by interferon-alpha (IFNα) and high surface levels of
tetherin suppress virus release even in the presence of Vpu [15,88].
Therefore, one possible therapeutic approach would be to enhance
tetherin expression by treatment with IFNα. It has been reported that
IFNα treatment in mice increases the levels of tetherin expression at
the cell surface [113]. In early studies, recombinant IFNα has been
used as a potential therapeutic for AIDS-associated Kaposi's sarcoma
caused by HHV-8 and some patients showed reduced HIV plasma
viremia [114]. Although IFNα levels are high in acute HIV-1 infection
[115], evidence suggests that impaired type I interferon production isobserved in AIDS patients [116]. A major problem with IFN-α
treatment is that it has both beneﬁcial effects – because it inhibits
viral replication – but also harmful consequences as it contributes to
the high levels of immune activation that drive progression to AIDS.
Alternatively, tetherin expression and/or activity may be enhanced
with the use of a compound drug. Interestingly, the cholesterol-
binding compound inhibitor amphotericin B methyl ester (AME),
previously shown to potently inhibit HIV-1 replication [117], was
recently shown to interfere with the anti-tetherin function of Vpu
[118]. Notably, recent data show that only the Vpu proteins of
pandemic HIV-1 group M (major) but not of non-pandemic HIV-1
group O (outlier) strains efﬁciently antagonize tetherin [105]. Thus,
efﬁcient induction of tetherin may not only inhibit viral replication
but potentially also reduce the rate of sexual transmission of HIV-1.
Accumulating data suggest that a number of restriction factors that
interfere with primate lentiviral replication and are counteracted by
other viral accessory genes remain to be identiﬁed [10,11]. For
example, the HIV-1 Vpr and the HIV-2 Vpx proteins bind DCAF1
(VprBP) to engage the Cullin4 E3-ubiquitin ligase complex [119–121].
This interaction seems to be required for the ability of Vpx to
antagonize an as-yet-unknown host restriction in human macro-
phages and dendritic cells [122,123]. Thus, the major function of the
majority of the HIV accessory genes seems to be the antagonism of
intrinsic immunity factors. However, HIV-1 also evolved sophisticated
mechanisms to manipulate cellular trafﬁcking, signal transduction
and gene expression. In particular, the accessory viral Nef protein is
well known for its ability to interact with a large variety of cellular
factors in order to render the infected cell and their environment
more conducive to viral replication and to facilitate viral immune
evasion [10,11,124,125]. Intact nef genes are required for efﬁcient
HIV-1 replication in infected individuals and are associated with
accelerated disease progression. Thus, agents disrupting the inter-
action of Nef with its cellular targetsmay have beneﬁcial effects on the
clinical course of infection.
4. Conclusions and future directions
Altogether the recent scientiﬁc advances demonstrate that the
interaction between HIV-1 and its human host is far more complex
than previously anticipated. The identiﬁcation of numerous cellular
factors that are exploited by HIV-1 at essentially every step of its
replication cycle provides a large number of potential targets for
antiretroviral therapy. However, a major challenge remains to
separate the wheat from the chaff and important questions must be
addressed before the bulk of this knowledge can be translated into
clinical applications; e.g. which cellular factors are obligatory for HIV-1
replication in the relevant primary cell types in vivo?; which essential
interactions between viral and host factors can be blocked without
signiﬁcant side effects?; which obligatory HIV-dependency factors can
be knocked-out without important physiological consequences?
Moreover, the identiﬁcation of a potential target does not necessarily
translate into the development of a therapeutic molecule. The
“druggability” of a candidate protein [126] depends both on its
propensity to be pharmacologically targeted — ideally an enzymatic
domainwhose endogenous binding partner can be out-competed by a
small drugmolecule— and on its ability to be efﬁciently delivered into
target cells. While much work still remains to be done, further studies
on the host proteins involved in HIV replication and their inhibition or
elimination are highly warranted, particularly since virological and
clinical analyses of the HIV-1-infected individual that received the
Δ32/Δ32 allogenic stem cell transplantation provide proof-of-concept
evidence that such strategies can achieve long-term control of viral
replication in the absence of antiretroviral therapy [39,41].
It is conceivable that HIV-1 has evolved to efﬁciently antagonize
those host defenses that are most relevant for its control. As discussed
above, our current knowledge suggests that intrinsic host restriction
319N. Arhel, F. Kirchhoff / Biochimica et Biophysica Acta 1802 (2010) 313–321factors are usually quite effective against retroviruses. Thus, it will be
interesting to further assess whether the efﬁcient induction of these
natural antiretroviral factors may overwhelm their viral antagonists
and thus allow HIV-1-infected individuals to gain better control over
viral replication. Finally, we should also consider that non-human
primates naturally infected with SIV avoid disease progression not
because they are able to efﬁciently control viral replication but
because they show limited immune activation and preserved mucosal
immunity [127,128]. Thus, not only strategies aiming to reduce viral
replication but also alternative approaches to limit the excessive
harmful levels of immune activation should be evaluated. Altogether,
the recent scientiﬁc advances in our understanding of viral patho-
genesis and on the cellular factors promoting or restricting HIV
replication hold great promise for the development of improved
treatment and prevention strategies.
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